Metastatic spinal cord compression in patients with cancer of unknown primary: Estimating the survival prognosis with a validated score

S. Douglas, S. E. Schild, D. Rades

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: This study aimed to create and validate a survival score for patients with metastatic spinal cord compression (MSCC) from cancer of unknown primary. Patients and methods: The entire cohort (n = 182) was divided into a test group (n = 91) and a validation group (n = 91). In the test group, eight pretreatment factors including age, gender, Eastern Cooperative Oncology Group performance status (ECOG-PS), number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, and time of developing motor deficits were retrospectively analyzed. Results: The score included the prognostic factors that were significant for survival in the multivariate analysis (ECOG-PS, ambulatory status, visceral metastases, time of developing motor deficits). The score for each factor was determined by dividing the 6-month survival rate by 10. Prognostic scores represented the sum of the scores for the four factors and ranged from 5 to 20 points. The 6-month survival rates were 5% for < 14 points, 41% for 14-16 points, and 92% for > 16 points (p < 0.001). In the validation group, the 6-month survival rates were 7%, 38%, and 91% (p < 0.001). Conclusion: This survival score can be considered valid and reproducible, since the survival rates of the validation group were comparable to those of the test group. This score can help when selecting the individual treatment and when counseling patients and relatives.

Original languageEnglish (US)
Pages (from-to)1048-1051
Number of pages4
JournalStrahlentherapie und Onkologie
Volume188
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Spinal Cord Compression
Survival Rate
Survival
Neoplasm Metastasis
Neoplasms
Age Factors
Counseling
Spine
Multivariate Analysis
Bone and Bones
Therapeutics

Keywords

  • Cancer of unknown primary
  • Metastatic spinal cord compression
  • Prognosis
  • Radiotherapy
  • Survival score

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

Metastatic spinal cord compression in patients with cancer of unknown primary : Estimating the survival prognosis with a validated score. / Douglas, S.; Schild, S. E.; Rades, D.

In: Strahlentherapie und Onkologie, Vol. 188, No. 11, 11.2012, p. 1048-1051.

Research output: Contribution to journalArticle

@article{34dbba2f588144c1b171b5b5c4b6e10e,
title = "Metastatic spinal cord compression in patients with cancer of unknown primary: Estimating the survival prognosis with a validated score",
abstract = "Background: This study aimed to create and validate a survival score for patients with metastatic spinal cord compression (MSCC) from cancer of unknown primary. Patients and methods: The entire cohort (n = 182) was divided into a test group (n = 91) and a validation group (n = 91). In the test group, eight pretreatment factors including age, gender, Eastern Cooperative Oncology Group performance status (ECOG-PS), number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, and time of developing motor deficits were retrospectively analyzed. Results: The score included the prognostic factors that were significant for survival in the multivariate analysis (ECOG-PS, ambulatory status, visceral metastases, time of developing motor deficits). The score for each factor was determined by dividing the 6-month survival rate by 10. Prognostic scores represented the sum of the scores for the four factors and ranged from 5 to 20 points. The 6-month survival rates were 5{\%} for < 14 points, 41{\%} for 14-16 points, and 92{\%} for > 16 points (p < 0.001). In the validation group, the 6-month survival rates were 7{\%}, 38{\%}, and 91{\%} (p < 0.001). Conclusion: This survival score can be considered valid and reproducible, since the survival rates of the validation group were comparable to those of the test group. This score can help when selecting the individual treatment and when counseling patients and relatives.",
keywords = "Cancer of unknown primary, Metastatic spinal cord compression, Prognosis, Radiotherapy, Survival score",
author = "S. Douglas and Schild, {S. E.} and D. Rades",
year = "2012",
month = "11",
doi = "10.1007/s00066-012-0130-3",
language = "English (US)",
volume = "188",
pages = "1048--1051",
journal = "Strahlentherapie und Onkologie : Organ der Deutschen R{\"o}ntgengesellschaft ... [et al]",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "11",

}

TY - JOUR

T1 - Metastatic spinal cord compression in patients with cancer of unknown primary

T2 - Estimating the survival prognosis with a validated score

AU - Douglas, S.

AU - Schild, S. E.

AU - Rades, D.

PY - 2012/11

Y1 - 2012/11

N2 - Background: This study aimed to create and validate a survival score for patients with metastatic spinal cord compression (MSCC) from cancer of unknown primary. Patients and methods: The entire cohort (n = 182) was divided into a test group (n = 91) and a validation group (n = 91). In the test group, eight pretreatment factors including age, gender, Eastern Cooperative Oncology Group performance status (ECOG-PS), number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, and time of developing motor deficits were retrospectively analyzed. Results: The score included the prognostic factors that were significant for survival in the multivariate analysis (ECOG-PS, ambulatory status, visceral metastases, time of developing motor deficits). The score for each factor was determined by dividing the 6-month survival rate by 10. Prognostic scores represented the sum of the scores for the four factors and ranged from 5 to 20 points. The 6-month survival rates were 5% for < 14 points, 41% for 14-16 points, and 92% for > 16 points (p < 0.001). In the validation group, the 6-month survival rates were 7%, 38%, and 91% (p < 0.001). Conclusion: This survival score can be considered valid and reproducible, since the survival rates of the validation group were comparable to those of the test group. This score can help when selecting the individual treatment and when counseling patients and relatives.

AB - Background: This study aimed to create and validate a survival score for patients with metastatic spinal cord compression (MSCC) from cancer of unknown primary. Patients and methods: The entire cohort (n = 182) was divided into a test group (n = 91) and a validation group (n = 91). In the test group, eight pretreatment factors including age, gender, Eastern Cooperative Oncology Group performance status (ECOG-PS), number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, and time of developing motor deficits were retrospectively analyzed. Results: The score included the prognostic factors that were significant for survival in the multivariate analysis (ECOG-PS, ambulatory status, visceral metastases, time of developing motor deficits). The score for each factor was determined by dividing the 6-month survival rate by 10. Prognostic scores represented the sum of the scores for the four factors and ranged from 5 to 20 points. The 6-month survival rates were 5% for < 14 points, 41% for 14-16 points, and 92% for > 16 points (p < 0.001). In the validation group, the 6-month survival rates were 7%, 38%, and 91% (p < 0.001). Conclusion: This survival score can be considered valid and reproducible, since the survival rates of the validation group were comparable to those of the test group. This score can help when selecting the individual treatment and when counseling patients and relatives.

KW - Cancer of unknown primary

KW - Metastatic spinal cord compression

KW - Prognosis

KW - Radiotherapy

KW - Survival score

UR - http://www.scopus.com/inward/record.url?scp=84867992912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867992912&partnerID=8YFLogxK

U2 - 10.1007/s00066-012-0130-3

DO - 10.1007/s00066-012-0130-3

M3 - Article

C2 - 23053138

AN - SCOPUS:84867992912

VL - 188

SP - 1048

EP - 1051

JO - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

JF - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

SN - 0179-7158

IS - 11

ER -